MedTrace Logo

Upadacitinib As a Novel Treatment for Refractory Eyelid Dermatitis

NCT06684522 · Status: NOT_YET_RECRUITING · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2024-11-12

No results posted yet for this study

Summary

This study aims to assess the efficacy of upadacitinib in eyelid dermatitis that has not resolved with topical therapies and patch testing.

Conditions

  • Eyelid Dermatitis

Interventions

DRUG

Upadacitinib 15 MG

Upadacitinib 15mg daily

Sponsors & Collaborators

Principal Investigators

  • Walter Liszewski · Northwestern University

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-12-31
Primary Completion
2026-03-31
Completion
2026-03-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06684522 on ClinicalTrials.gov